NVS stock price forecast for mid-2024 suggests moderate upside potential, with consensus target set at $ And then, of course, we have YTB now in either phase 1 or phase 2 development for immune reset. That's our rapid CAR-T therapy. I think now enrolling in six or seven indications, continuing to look to expand across immunology as well as in neuroscience indications. And so, I think, our BD and M&A efforts are either to bolster the areas I just mentioned by specifics or cell therapies, or to look at novel targets like Monte Rosa that we recently have done. Oncology remains one of the most important fields in biotech. An emerging subsector is radioactive cancer treatments , which Novartis is pioneering. In the industry, this is known as radioligand therapy. NVS stock price forecast maintains a positive trajectory with projected year-end target of $111, banking on sustained market share capture in chronic disease therapies and strategic acquisitions.